NPS Pharmaceuticals Company Profile (NASDAQ:NPSP)

About NPS Pharmaceuticals

NPS Pharmaceuticals logoNPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on delivering therapies that transform the lives of patients with rare diseases. The Company's primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved the United States Food and Drug Administration (FDA) for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The Company's second principal product, Natpara (recombinant human parathyroid hormone 1-84 [rDNA origin] injection, has been developed for hypoparathyroidism, a rare multidimensional disorder characterized by deficient or absent parathyroid hormone (PTH). The Company has collaborations or royalty agreements with Amgen, Janssen, GlaxoSmithKline and Kyowa Hakko Kirin.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: NPSP
  • CUSIP: 62936P10
Key Metrics:
  • Previous Close: $46.00
  • 50 Day Moving Average: $46
  • 200 Day Moving Average: $34
  • 52-Week Range: $22.00 - $46.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 23.00
  • P/E Growth: 0
  • Market Cap: $N/A
Additional Links:
Companies Related to NPS Pharmaceuticals:

Analyst Ratings

Consensus Ratings for NPS Pharmaceuticals (NASDAQ:NPSP) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for NPS Pharmaceuticals (NASDAQ:NPSP)
No equities research coverage for this company has been tracked by


Earnings History for NPS Pharmaceuticals (NASDAQ:NPSP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/18/2015Q414$0.06($0.02)$69.30 million$66.70 millionViewN/AView Earnings Details
11/10/2014Q314$0.01($0.02)$59.50 million$57.20 millionViewN/AView Earnings Details
8/6/2014Q214$0.02$53.06 million$56.10 millionViewListenView Earnings Details
5/8/2014Q114($0.02)($0.06)$48.30 million$44.04 millionViewListenView Earnings Details
2/27/2014Q413$0.02$0.07$44.22 million$54.45 millionViewListenView Earnings Details
11/6/2013Q313($0.02)($0.01)$38.40 million$39.20 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)($0.13)$31.62 million$36.50 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.13)($0.09)$27.56 million$25.43 millionViewListenView Earnings Details
2/21/2013Q4 2012($0.09)($0.14)$28.93 million$27.10 millionViewListenView Earnings Details
11/9/2012Q312($0.16)($0.04)$28.18 million$27.02 millionViewN/AView Earnings Details
8/1/2012($0.09)$0.08ViewN/AView Earnings Details
5/3/2012($0.11)($0.12)ViewN/AView Earnings Details
2/15/2012($0.11)($0.10)ViewN/AView Earnings Details
11/3/2011($0.10)($0.14)ViewN/AView Earnings Details
8/2/2011($0.07)($0.07)ViewN/AView Earnings Details
5/3/2011($0.12)($0.13)ViewN/AView Earnings Details
2/15/2011($0.20)($0.09)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for NPS Pharmaceuticals (NASDAQ:NPSP)
Current Year EPS Consensus Estimate: $1 EPS
Next Year EPS Consensus Estimate: $2 EPS


Dividend History for NPS Pharmaceuticals (NASDAQ:NPSP)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for NPS Pharmaceuticals (NASDAQ:NPSP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
2/10/2015Susan E GrafVPSell6,711$45.87$307,833.57View SEC Filing  
12/17/2014Joseph J RogusSVPSell16,467$35.00$576,345.00View SEC Filing  
12/17/2014Luke M BesharCFOSell52,258$35.00$1,829,030.00View SEC Filing  
12/17/2014Rachel R SeliskerDirectorSell3,708$34.59$128,259.72View SEC Filing  
12/8/2014Rachel R SeliskerDirectorSell23,157$34.50$798,916.50View SEC Filing  
11/28/2014Rachel R SeliskerDirectorSell11,635$34.50$401,407.50View SEC Filing  
11/17/2014Joseph J RogusSVPSell26,782$30.00$803,460.00View SEC Filing  
11/11/2014Rachel R SeliskerDirectorSell15,188$29.50$448,046.00View SEC Filing  
10/31/2014Luke M BesharCFOSell10,000$29.00$290,000.00View SEC Filing  
10/27/2014Luke M BesharCFOSell30,635$26.75$819,486.25View SEC Filing  
2/13/2014Georges GemayelDirectorSell6,188$37.70$233,287.60View SEC Filing  
1/8/2014Luke BesharCFOSell31,588$35.01$1,105,895.88View SEC Filing  
12/26/2013Luke BesharCFOSell37,874$30.02$1,136,977.48View SEC Filing  
12/23/2013James GroningerDirectorSell3,000$29.50$88,500.00View SEC Filing  
12/18/2013Ed StratemeierSVPSell205,432$25.13$5,162,506.16View SEC Filing  
9/20/2013Luke BesharCFOSell50,000$30.26$1,513,000.00View SEC Filing  
9/16/2013Joseph RogusVPSell25,312$28.11$711,520.32View SEC Filing  
9/16/2013Luke BesharCFOSell50,000$27.89$1,394,500.00View SEC Filing  
8/30/2013Roger GarceauCMOSell110,000$25.18$2,769,800.00View SEC Filing  
8/20/2013James GroningerDirectorSell16,900$23.21$392,249.00View SEC Filing  
5/9/2013Luke M BesharCFOSell45,150$14.18$640,227.00View SEC Filing  
11/15/2012Glenn R MelroseSVPBuy11,000$9.09$99,990.00View SEC Filing  
10/3/2012Roger GarceauCMOSell140,625$9.51$1,337,343.75View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for NPS Pharmaceuticals (NASDAQ:NPSP)
News IconNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Valuation According To Analysts - UK Market News (NASDAQ:NPSP) - February 24 at 9:03 AM logoRegeneron Pharmaceuticals : Tony Coles, M.D., Elected to Regeneron Board of Directors (NASDAQ:NPSP) - February 1 at 7:59 PM
News IconTony Coles elected to Regeneron board of directors (NASDAQ:NPSP) - February 1 at 7:59 PM
News IconWatch President's Speech To Republicans With UK Prime Minister Theresa May (NASDAQ:NPSP) - January 28 at 5:05 AM logoSyndax Pharmaceuticals (SNDX) Names Pierre Legault to Board of Directors (NASDAQ:NPSP) - January 6 at 2:13 AM logoSyndax Adds Global Pharmaceutical Business Veteran to Board of Directors (NASDAQ:NPSP) - January 5 at 9:02 PM
News IconVC-backed Enterome hires Patel as chief medical officer and adds Garceau to board (NASDAQ:NPSP) - December 9 at 6:50 PM
News IconEnterome Further Strengthens its Leadership Team and Board Adding Clinical Development Experience (NASDAQ:NPSP) - December 9 at 8:54 AM logoKyle Bass Group Gets 1st Win As PTAB Nixes Gattex Claims (NASDAQ:NPSP) - October 31 at 1:12 PM
News IconNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Updated Analyst Coverage - NewsDen (NASDAQ:NPSP) - October 15 at 11:08 AM
News IconReport explores the hyperparathyroidism market analysis, epidemiology and opportunities for 2023 (NASDAQ:NPSP) - October 14 at 6:14 PM
News IconNPS Pharmaceuticals, Inc. (NASDAQ:NPSP) Analyst Review - NewsDen (NASDAQ:NPSP) - October 14 at 9:43 AM logoAdvaxis, Inc. (NASDAQ:ADXS) Files an 8k - Market Exclusive (NASDAQ:NPSP) - October 4 at 6:05 PM logoShire (SHPG) Gets EU Nod for Label Expansion of Revestive (NASDAQ:NPSP) - July 8 at 6:34 PM logoGaps Up Stocks Summary, June 3 - TLOG, RXDX, VLTC, CONN, PL, GIGA, NPSP - (NASDAQ:NPSP) - June 3 at 6:59 PM logoGaps Up Stocks Summary, June 3 – TLOG, RXDX, VLTC, CONN, PL, GIGA, NPSP (NASDAQ:NPSP) - June 3 at 9:21 AM logoA Deep Dive Into Shire's Business - Seeking Alpha (NASDAQ:NPSP) - May 30 at 4:40 PM logoShire Quarterly Profit Tops Estimates as Drug Sales Soar (1) (NASDAQ:NPSP) - May 1 at 3:04 AM logoCompany Overview of NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) - April 11 at 10:07 PM logoSmart-Money Healthcare Investing Focuses On Major Biotech Stocks - Seeking Alpha (NASDAQ:NPSP) - March 28 at 4:33 PM logoNPS Pharmaceuticals, Inc. Company Profile (NASDAQ:NPSP) - February 25 at 4:46 PM logoChancery OKs Shareholder Deal On $5.2B NPS-Shire Sale (NASDAQ:NPSP) - February 19 at 9:01 AM
News IconShire Delivers Record Full-year Revenue & Strong Double Digit Growth In Non GAAP Diluted Earnings Per ADS. Las Vegas Blog (NASDAQ:NPSP) - February 11 at 3:48 PM logoShire Fourth-Quarter Earnings Exceed Analysts' Expectation (NASDAQ:NPSP) - February 11 at 9:02 AM logoShire target NPS Pharma wins FDA approval for Natpara (NASDAQ:NPSP) - January 26 at 3:43 AM logoShire shares jump as drug approval vindicates $5.2 bln NPS purchase (NASDAQ:NPSP) - January 26 at 3:16 AM logoU.S. FDA approves NPS drug, in move validating Shire takeover deal (NASDAQ:NPSP) - January 23 at 7:39 PM logoFDA approves NPS drug, in move validating Shire takeover deal (NASDAQ:NPSP) - January 23 at 7:00 PM logo[video]Jim Cramer's 'Mad Money' Recap: Blame Tech, Oil and Retail for Today's Losses (NASDAQ:NPSP) - January 12 at 8:32 PM logoU.S. equities end lower... (NASDAQ:NPSP) - January 12 at 4:45 PM logoShire acquires US rival NPS Pharmaceuticals for $5.2bn (NASDAQ:NPSP) - January 12 at 8:18 AM logoNPS a "natural fit" for pharma group Shire, says UBS (NASDAQ:NPSP) - January 12 at 6:21 AM logoCramer: Hold Your Fire (NASDAQ:NPSP) - January 12 at 5:17 AM logoShire to buy NPS for $5.2 billion to boost rare disease drugs (NASDAQ:NPSP) - January 11 at 3:27 PM logoShire to buy NPS for $5.2 bln to boost rare disease drugs (NASDAQ:NPSP) - January 11 at 3:25 PM logoShire to buy specialty drugmaker NPS Pharma for $5.2 billion (NASDAQ:NPSP) - January 11 at 1:27 PM logoShire considering bid for NPS Pharmaceuticals - Bloomberg (NASDAQ:NPSP) - December 17 at 12:06 PM logoNPS reports 3Q loss (NASDAQ:NPSP) - November 10 at 4:39 PM


What is NPS Pharmaceuticals' stock symbol?

NPS Pharmaceuticals trades on the NASDAQ under the ticker symbol "NPSP."

How do I buy NPS Pharmaceuticals stock?

Shares of NPS Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NPS Pharmaceuticals stock cost?

One share of NPS Pharmaceuticals stock can currently be purchased for approximately $46.00.

NPS Pharmaceuticals (NASDAQ:NPSP) Chart for Friday, February, 24, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)

Earnings History Chart

Earnings by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)

Dividend History Chart

Dividend Payments by Quarter for NPS Pharmaceuticals (NASDAQ:NPSP)

Last Updated on 2/24/2017 by Staff